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Abstract
Solid drug nanoparticles (SDNs) are a nanotechnology with favourable characteristics to
enhance drug delivery and improve the treatment of several diseases, showing beneﬁt
for improved oral bioavailability and injectable long-acting medicines. The physicochem-
ical properties and composition of nanoformulations can inﬂuence the absorption, distri-
bution, and elimination of nanoparticles; consequently, the development of
nanoparticles for drug delivery should consider the potential role of nanoparticle charac-
teristics in the deﬁnition of pharmacokinetics. The aim of this study was to investigate the
pharmacological behaviour of efavirenz SDNs and the identiﬁcation of optimal nanoparti-
cle properties and composition. Seventy-seven efavirenz SDNs were included in the analy-
sis. Cellular accumulation was evaluated in HepG2 (hepatic) and Caco-2 (intestinal), CEM
(lymphocyte), THP1 (monocyte), and A-THP1 (macrophage) cell lines. Apparent intestinal
permeability (Papp) was measured using a monolayer of Caco-2 cells. The Papp values were
used to evaluate the potential beneﬁt on pharmacokinetics using a physiologically based
pharmacokinetic model. The generated SDNs had an enhanced intestinal permeability
and accumulation in different cell lines compared to the traditional formulation of
efavirenz. Nanoparticle size and excipient choice inﬂuenced efavirenz apparent perme-
ability and cellular accumulation, and this appeared to be cell line dependent. These ﬁnd-
ings represent a valuable platform for the design of SDNs, giving an empirical background
for the selection of optimal nanoparticle characteristics and composition. Understanding
how nanoparticle components and physicochemical properties inﬂuence pharmacological
patterns will enable the rational design of SDNs with desirable pharmacokinetics.
© 2016 The Authors. Journal of Interdisciplinary Nanomedicine published by John Wiley & Sons Ltd and the British Society for Nanomedicine
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
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Introduction
Efﬁcacy and safety of therapies are inﬂuenced by the
distribution of active pharmaceutical ingredients
(APIs) into tissues and organs. The pharmacokinetics
of APIs can be complicated by several processes such
as poor absorption, low penetration in target tissues,
and high metabolism and elimination rates.
Nanoformulations have been applied to tackle these
issues and enhance the delivery of APIs, exploiting
the speciﬁc and unique properties of sub-micron parti-
cles. A broad spectrum of nanomedicine platforms for
drug delivery has been developed using different
technologies for improving pharmacokinetics, or ac-
tive and passive targeting. APIs can be loaded into
nanocarriers (e.g. liposomes, nanoemulsions, poly-
meric nanoparticles) to prevent chemical or enzymatic
degradation and mediate enhanced penetration into
cells, tissues, and organs (Marrache et al., 2013). Di-
rect conjugation of APIs to polymers has been devel-
oped to increase circulatory times and allow the
controlled release of APIs (Joralemon et al., 2010).
Additionally, drugs can be linked to different inorganic
nanoparticles, such as gold (Thakor et al., 2011),
silver (Ong et al., 2013), silica (Wu et al., 2013), and
iron (Ittrich et al., 2013).
Solid drug nanoparticles (SDNs) do not involve a
nanocarrier system. Rather, the nanoparticle is con-
structed of the API, which is stabilised by polymer
and/or surfactant excipients (Zhang et al., 2008). SDNs
have proven successful with approved medicines show-
ing beneﬁt for improved bioavailability of poorly solu-
ble APIs (Deschamps et al., 2009; McDonald et al.,
2014), sustained release (Weir et al., 2013; Lyseng-
Williamson and Keating, 2002; Markowitz et al., 2003;
Portenoy et al., 2002), or overcoming food effects
(Deschamps et al., 2009; Haessler et al., 2008), after
oral dosing. SDN formulations have also found applica-
tion for long-acting medicines where therapeutic
plasma concentrations of the API are maintained for
weeks or months after a single dose (van’t Klooster
et al., 2010; Baert et al., 2009; Spreen et al., 2013;
Samtani et al., 2009).
Poor solubility and low bioavailability are continu-
ing issues for drug development programmes in the
pharmaceutical industry. Around 60% of new drug can-
didates have low solubility in water and biological
ﬂuids, and many have failed during development,
having a detrimental effect on the success of novel
therapies (Sareen et al., 2012; Sikarra et al., 2012).
Many antiretroviral drugs are characterised by low
aqueous solubility with poor and variable bioavailabil-
ity. The absorption of APIs with poor solubility can be
inﬂuenced by concomitant food intake, because of
the presence of lipids increasing drug solubility
(Squibb, 1999), malnutrition, and inﬂammatory bowel
disease deﬁning large inter-patient variability (de
Roche et al., 2012). For antiretrovirals, as with many
other drugs, poor oral bioavailability is exacerbated in
special populations, for which the intestinal anatomy
and physiology can complicate absorption (Fernandez
et al., 2011). The improvement of dissolution through
nanoformulation strategies has the potential of reduc-
ing variability between patients, dose reduction, and
safer treatment of special populations. We have pre-
viously described the formation of SDNs using a novel
and scalable manufacturing process (Zhang et al.,
2008; McDonald et al., 2014; McDonald et al., 2012).
Moreover, efavirenz SDNs created using this approach
exhibited advantages for oral bioavailability in pre-
clinical species (McDonald et al., 2014).
The physicochemical properties and composition of
nanoformulations can impact the pharmacokinetics of
nanoparticles. The size of nanoparticles has a major
determining effect on their movement across biolog-
ical barriers and penetration into tissues and organs.
The importance of surface charge, charge density,
roughness, and ligand hydrophobicity on the cellular
uptake of silica nanoparticles has been recently in-
vestigated (Xue et al., 2013; Schrade et al., 2012).
Additionally, commonly used excipients can impact
upon the expression and activity of metabolic en-
zymes, suggesting that nanoparticle components have
the potential to inﬂuence processes involved in ab-
sorption, distribution, metabolism, and elimination
(ADME) of traditional drugs and nanoparticles (Martin
et al., 2013). Consequently, the development of
nanoparticles for drug delivery should consider the
potential role of nanoparticle properties in the deﬁ-
nition of pharmacokinetics, but these effects are
likely to be composition dependent, and there are
signiﬁcant knowledge gaps that necessitate further
investigation.
There is currently no published data showing the
inﬂuence of particle properties on pharmacological
characteristics of SDN formulations. Therefore, the
aim of this work was to assess how nanoparticle proper-
ties relate to cellular accumulation and intestinal
permeability in a library of SDNs manufactured from
the same API (efavirenz) but stabilised using various
excipients.
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Experimental Section
Preparation of emulsion-templated freeze-dried
monoliths containing efavirenz SDNs (physical
science method)
14C-labelled Efavirenz (speciﬁc activity: 56.7mCi/mmol
– radiochemical purity: 99.8%) was purchased from
Moravek Biochemicals Inc. (Brea, CA, US). Stock solu-
tions of efavirenz (EFV, 70mg/mL – choloroform), poly-
mers (22.5mg/mL – water), and surfactants (22.5mg/
mL – water) were prepared. A solution containing a ﬁnal
solid mass ratio of 10% efavirenz:75% polymer and 15%
surfactant in a 1:4 chloroform to water mixture was pre-
pared. Each sample was emulsiﬁed using a Covaris S2x
acoustic homogenisation system for 30 s with a duty cy-
cle of 20, an intensity of 10 and 500 cycles/burst, in fre-
quency sweeping mode. Following emulsiﬁcation, the
sample was frozen and lyophilised using a Virtis bench-
top K freeze-drier for 42 h to form a nanoparticle-
containing porous monolith. 14C-labelled efavirenz was
added to the stock solution to generate radioactive
nanoparticles of efavirenz.
Excipients included various combinations of polymer
such as polyethylene glycol 1 k (PEG1k), Pluronic F68,
Pluronic F127, kollicoat protect, polyvinyl alcohol
(PVA), polyvinylpyrrolidone 30 k (PVP30k), hydroxypro-
pyl methylcellulose (HPMC), hydrolysed gelatine, and
sodium carboxymethyl cellulose (NaCMC) and surfac-
tant such as sodium alginate, sodium deoxycholate, so-
dium caprylate, vitamin E PEG succinate (Vit-E PEG),
Sisterna 11, Sisterna 16, sodium dodecyl sulphate
(SDS), dioctyl sodium sulfosuccinate (AOT), cremophor,
solutol HS, Tween 20, Tween 80, Brij58, hyamine, and
cetrimonium bromide (CTAB).
Physicochemical characterisation (physical
science method)
Monoliths were dispersed in 3.5mL of water and Zeta
potential (electrical charge characteristics of the parti-
cles), particle size, and polydispersity index (heteroge-
neity of particle sizes) of the resulting nanoparticle
dispersion were determined at a temperature of 25°C
by dynamic light scattering using a Malvern Zetasizer
Nano ZS equipped with a 4-mW He–Ne, 633-nm laser.
Malvern Zetasizer software version 6.20 was used for
data analysis. Measurement of the zeta potential was
carried out using disposable capillary zeta cells, at pH
of 6.5 and 25°C. Size, zeta potential, and polydispersity
index measurements were obtained as an average of
three individual measurements. Pharmacological
evaluations were conducted on 77 formulations, which
formed reproducible stable nanodispersions when
reconstituted in water.
Cell culture/cell maintenance (life science
method)
HepG2 (hepatic) and Caco-2 (intestinal) cells were pur-
chased from American Type Culture Collection (ATCC;
USA). Cells were maintained in Dulbecco’s modiﬁed ea-
gle’s medium (DMEM; Sigma; Dorest, UK) supplemented
with 10% foetal bovine serum (FBS; Bio-Whittaker,
Berkshire, UK) for HepG2 cells, and 15% sterile ﬁltered
FBS for Caco-2 cells. THP1 (monocyte) cells were pur-
chased from the European Collection of Cell Culture
(ECACC; Porton Down, UK) and grown in RPMI-1640
(Sigma; Dorest, UK) supplemented with 10% sterile ﬁl-
tered FBS. Adherent cells (HepG2 and Caco-2) were
routinely sub-cultured every 4 days when 95% conﬂu-
ent. THP1 cells were sub-cultured when a density of
1 × 106 cells/mL was achieved. THP1 cells were
activated to macrophage-like cells (ATHP1) by the addi-
tion of phorbol 12-myristate 13 acetate (PMA: Sigma;
Dorest, UK) to a ﬁnal concentration of 10nM in
THP1 culture medium (RPMI-1640 supplemented with
10% sterile ﬁltered FBS). Cells were then incubated at
37°C and 5% CO2 for 7 days prior to use to allow differ-
entiation from monocytes to macrophage-like cells.
Cell count and viability were determined by Trypan
Blue exclusion assay. The range of passage number af-
ter receipt from ATCC or ECACC was equal to 4 – 7 for
HepG2, 5 – 8 for Caco-2, 8 – 10 for THP-1, 8 – 10 for
CEM, and 8 – 10 for ATHP-1.
Cellular accumulation in hepatic, intestinal, and
immune cell lines (life science method)
HepG2, Caco-2, THP1, and CEM cells were separately
seeded into each well of a six-well plate (NunclonTM,
Denmark) at a density of 5 × 106 cells per well in
FBS supplemented DMEM (Sigma, UK) and incubated at
37°C and 5% CO2 for 24 h. THP1 cells were seeded at a
density of 5 × 106 cells per well in a six-well plate and
allowed to differentiate to ATHP1 for 7days in the pres-
ence of 10-nM PMA supplemented RPMI-1640 and 10%
FBS media. For HepG2, Caco-2, and ATHP1, cells were
washed with HBSS (37°C) then replaced with HBSS
(37°C) containing efavirenz (10μM/0.1μCi 14C
efavirenz; <0.1% DMSO) or efavirenz nanodispersions
(10μM/0.1μCi 14C efavirenz). After 60-min incubation
at 37°C and 5% CO2, 100μL of the extracellular solution
was sampled. The remaining media was removed, and
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cells washed twice in ice cold HBSS. The ice cold HBSS
was replaced with 500μL of water and the plates incu-
bated for 24 h at 20°C to lyse the cells. For THP1 and
CEM cells, 5 × 106 cells were separately dispensed into
tubes and centrifuged at 50 ×g at room temperature
for 1min. The supernatant was aspirated, and cells
were washed twice with HBSS (37°C). Subsequently,
600μL of HBSS (37°C) containing efavirenz (10μM/
0.1μCi 14C efavirenz; <0.1% DMSO) or efavirenz
nanodispersions (10μM/0.1μCi 14C efavirenz) was
added to the cells and incubated for 60min at 37°C
and 5% CO2. The samples were then centrifuged at
50 ×g for 3min at 4°C, and 100-μL supernatant was sam-
pled. The cell pellet was washed twice in ice cold HBSS
with centrifugation at 50 ×g for 3min at 4°C. The cell
pellet was lysed using 100μL of ice cold tap water.
The crude lysate was then vortexed for 30 s and trans-
ferred to a scintillation vial before incubation for 24 h
at 20°C. Finally, 4mL of Ultima Gold liquid scintilla-
tion cocktail ﬂuid was added to all samples, and radio-
activity was detected using a Perkin Elmer 3100TS
scintillation counter. Average cell volumes were quanti-
ﬁed using the Scepter 2.0 Handheld Automated Cell
Counter from Merck Millipore. A cellular accumulation
ratio (CAR) was then calculated as the ratio of intracel-
lular to extracellular concentration.
Quantiﬁcation of efavirenz metabolite (life
science method)
For HepG2 and ATHP1, cells were washed with HBSS
(37°C) then replaced with HBSS (37°C) containing
efavirenz (20μM <0.1% DMSO) or efavirenz
nanodispersions (20-μM efavirenz). After 60-min incu-
bation at 37°C and 5% CO2, 500μL of the extracellular
solution was sampled. The remaining media was
removed and cells washed twice in ice cold HBSS. The
ice cold HBSS was replaced with 500μL of trypsin and
the plates incubated for 10min 37°C and 5% CO2. Cell
suspension was then centrifuged at 2000 rpm, 4°C for
5min. The resulting cell pellet was resuspended in
1mL of FBS supplemented DMEM. Subsequently, 500μL
was removed for extraction and analysis via HPLC.
Caco-2 cells were treated as above. For THP1 and CEM
cells, 5 × 106 cells were separately dispensed into tubes
and centrifuged at 50 ×g at room temperature for 1min.
The supernatant was aspirated, and cells were washed
twice with HBSS (37°C). Subsequently, 1mL of HBSS
(37°C) containing efavirenz (20μM <0.1% DMSO) or
efavirenz nanodispersions (20-μM efavirenz) was added
to the cells and incubated for 60min at 37°C and 5%
CO2. The samples were then centrifuged at 50 ×g for
3min at 4°C, and 500μL supernatant was sampled.
The cell pellet was washed twice in ice cold HBSS with
centrifugation at 50 ×g for 3min at 4°C. The cell pellet
was resuspended in 1mL of FBS supplemented DMEM.
Subsequently, 500μL was removed for extraction and
analysis via HPLC.
Samples of media and cell suspension were treated
with an excess of ACN (5:1 v/v). Samples were then
thoroughly vortexed followed by centrifugation at
4000 RCF, 4°C for 10min. The supernatant was then
transferred to fresh glass vials and placed in a rotary
evaporator overnight at room temperature. Samples
were then reconstituted in ACN:H2O (20:80% V/V) and
analysed via HPLC.
HPLC was performed on a Dionex system (Thermo,
UK) using a Fortis C18 column. Two mobile phases
were used in the chromatographic run, mobile Phase
A (95% dH2O, 5% ACN, 5mM NH4FA) and mobile phase
B (90% ACN, 10% H2O). Chromotagraphic run was con-
ducted using a mobile phase gradient with a ﬂow rate
of 1mLmin1. At the start of the run, mobile phase A
was 100% until 0.1min when mobile phase B was in-
creased to 92% at 0.5min. Mobile phase B was then
gradually increased to 93% over 5min. Mobile phase
B was then increased to 100% at 5.6min which was
held until 6.5min. Mobile Phase A was then increased
to 100% and held till the termination of the run at
8.55min. Efavirenz and 8-hydroxyefavirenz were de-
tected using a Dionex UV detector at wavelengths
220 and 254.
Apparent permeability (Papp) of efavirenz across
Caco-2 cell monolayers (life science method)
Caco-2 cells were cultured as previously described
(Moss et al., 2011). Caco-2 cells were seeded onto poly-
carbonate membrane transwell plates at a density of
5 × 105 cells/cm2; media was replaced initially after
24 h and subsequently every 48 h. Transwell plates were
cultured for 21 days, and monolayer integrity was eval-
uated through the quantiﬁcation of the transepithelial
electrical resistance (TEER). TEER values of
>650Ω cm2 were deemed indicative of an acceptably
conﬂuent monolayer for trancellular permeation as-
says. The TEER value has been measured using STX2
electrodes. One set of electrodes was placed in the api-
cal compartment and the other in the basolateral com-
partment. Efavirenz (10μM/0.1μCi 14C efavirenz;
<0.1% DMSO) or efavirenz nanodispersions (10μM/
0.1μCi 14C efavirenz) were added to the donor chamber
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to quantify transport in the apical to basolateral (A>B)
direction. Media was sampled on an hourly basis over
4 h. Apparent permeability coefﬁcient (Papp) was then
determined by the amount of efavirenz transported
over time using the following equation:
Papp ¼ dQ=dtð Þ 1= AxC0ð Þð
where A is the surface area of the transwell, C0 is
the starting concentration of efavirenz in the
donor chamber (10μM), and (dQ/dt) is the amount
per time (nmol s1).
Validation of size model by prediction of
apparent permeability (Papp) for scaled
efavirenz SDNs (life science method)
The efavirenz SDNs presented within this manuscript
contained 10wt% efavirenz relative to the polymer
and surfactant excipients in the dry state. As part of
the translation towards clinical utility, the drug load-
ing was pushed to 70wt% efavirenz as previously de-
scribed (McDonald et al., 2014). Therefore, in order
to test the validity of Papp-prediction from particle
size, the model was validated with the previously pub-
lished 70wt% efavirenz SDNs. For this, particle size of
the 70wt% SDNs (not included in the model develop-
ment) was used to predict the Papp for these formula-
tions. Validation was conducted by regression of
predicted Papp against observed Papp and construction
of Bland and Altman plots as previously described
(Bland and Altman, 1986).
Prediction of bioavailability and
pharmacokinetics by physiologically-based
pharmacokinetic (PBPK) modelling (life science
method)
The Papp values were used to evaluate the potential
beneﬁt on bioavailability and pharmacokinetics gener-
ated by the SDNs. A semi-mechanistic physiologically
based pharmacokinetic model for efavirenz was devel-
oped as previously described (McDonald et al., 2014;
Siccardi et al., 2013). The model is based on the as-
sumption that following oral administration the SDNs
are not reaching the systemic circulation but are only
affecting the absorption process. Once efavirenz has
permeated the intestinal wall, it diffuses into the
blood stream following distribution patterns similar
to the traditional formulation. Efavirenz pharmacoki-
netics were simulated through a PBPK model devel-
oped using Berkeley Madonna (version 8.3.18,
University of California, CA, USA). Experimental
in vitro data describing the physiochemical properties,
metabolism, and induction potential of efavirenz were
obtained from previously published reports (Ogburn
et al., 2010; Ward et al., 2003). The total hepatic
clearance was calculated considering the expression
of cytochrome P450, amount of microsomal protein
per gram of liver, liver weight, and regional blood
ﬂows (Crewe et al., 2011; Ohtsuki et al., 2012). A
population physiology model (physB) was used to gen-
erate virtual patients. Organ weights and blood ﬂows
were allometrically scaled to an individual’s charac-
teristics as previously described (Bosgra et al.,
2012). Papp in Caco-2 cells was used to derive the
constant of absorption (ka) and oral bioavailability
and then integrated in a compartmental absorption
and transit model. Efavirenz distribution was simu-
lated considering plasma to tissue ratio (Poulin and
Theil, 2002), organ volumes, and blood ﬂows. The
pharmacokinetics of the conventional formulation
and SDNs of efavirenz were simulated considering a
600mg once daily dose, administered to 50 virtual
subjects (20–50 years old, 0.5 proportion females) for
21 days.
Statistical analysis (life science method)
Data were assessed for normality using a Shapiro–Wilk
test. Categorical data were analysed using a
Mann–Whitney test. Spearman’s rank correlation was
used to investigate continuous data. Univariate and
stepwise-elimination multivariate logistic regression
analyses were conducted to characterise (1) the effect
of chemical composition on physicochemical proper-
ties, (2) the effect of physicochemical properties on
CAR and Papp, and (3) the effect of chemical composi-
tion on CAR and Papp.
Results
Physicochemical properties (physical science
results)
A total of 77 efavirenz SDNs were included in the
analysis. Measured z-average diameter, polydispersity
index and zeta-potential (mean± SD) were 280 ±
254 nm, 0.33 ± 0.19 and 10.7 ± 21.8mV, respectively.
A total of 65 out of 77 SDNs were characterised by nega-
tive zeta potential. The effect of SDN composition on
size was investigated using multivariate linear regres-
sion. As represented in Figure 1A and B, Log10 z-average
diameter was correlated with PVA (β =0.26, p = 0.002),
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F127 (β =0.802, p = 0.0001), NaCMC (β = 0.542, p =
0.0001), AOT (β =0.318, p =0.02), and cremophor
(β =0.27, p = 0.001). As represented in Figure 1C and
D, zeta potential was correlated with CTAB (β = 36.7,
p = 0.0001), hyamine (β = 33.7, p = 0.0001), PEG 1 k
(β =19.2, p = 0.0001), SDS (β =31.7, p = 0.001), so-
dium deoxycholate (β =27.8, p =0.002), AOT (β =
13.5, p = 0.02), and PVA (β =10.4, p = 0.026).
Cellular accumulation in hepatic, intestinal, and
immune cell lines (life science results)
For the efavirenz SDNs (relative to aqueous efavirenz
control), CAR ranged from 49 to 458 (77 for aqueous
control) for CEM, 115 to 842 (202 for aqueous control)
for THP1, 138 to 682 (496 for aqueous control) for
ATHP1, 389 to 1163 (901 for aqueous control) for
Caco-2, and 107 to 730 for HepG2 (682 for aqueous con-
trol). The CAR of efavirenz SDNs was then compared
with the accumulation of aqueous solution of efavirenz.
The CAR was higher for 73% of SDNs in THP1 cells, 3% in
ATHP1 cells, 88% in CEM cells, 7% in HEPG2 cells, and
21% in Caco-2 cells. As represented in Figure 2A, log10
z-average diameter was correlated with CAR in CEM
(r = 0.349, p = 0.002) but was not signiﬁcant for other
cell lines (Fig. 2B–E). Zeta potential was correlated
with CAR in Caco-2 (rho = 0.258, p = 0.023) and HepG2
(rho =0.230, p = 0.045). The results of the univariate
and multivariate regression analysis for the different
cell lines are summarised in Supplemental Tables 1–5.
F68 (β = 0.14, p = 0.014), sodium alginate (β = 0.202,
p = 0.007), sisterna 16 (β = 0.298, p = 0.004), and Tween
80 (β =0.178, p = 0.004) were identiﬁed as associated
with the accumulation in THP1. CAR in Caco-2 cells
was associated with zeta potential (β = 0.001,
p = 0.023) and with PEG1K (β =0.12, p =0.0001).
PEG1K (β =0.103, p = 0.01), PVA (β = 0.072, p = 0.047),
NaCMC (β = 0.197, p = 0.01), and Brij58 (β = 0.103,
p = 0.014) in ATHP1 cells. Particle size (β = 0.257
p = 0.0001), F127 (β =0.272 p = 0.002), and Solutol HS
(β =0.183 p = 0.015) were associated with CAR in CEM
cells. For HepG2 cells, zeta potential (β = 0.001
p = 0.029), log10 polydispersity index (β =0.113
p = 0.044), F68 (β =0.107 p = 0.001), NaCMC (β =0.137
p = 0.006), and Na deoxycholate (β =0.474 p = 0.0001)
were identiﬁed as factors associated with CAR.
Quantiﬁcation of efavirenz metabolite (life
science results)
The peak height and area of the extracted samples
were recorded (Supplemental Table 6) and compared
Figure 1. Nanoparticle size (A–B) and zeta potential (C–D) by poly-
mers and surfactants. Bars represent mean value, and error bars
represent standard error of the mean. Grey bars highlight factors
signiﬁcantly associated with the relevant physical property
through regression analysis (P< 0.05).
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to a chemical mix of efavirenz (retention time 5.4min)
and 8-hydroxyefavirenz (retention time 4.9min)
(5000 ngmL1). The table shows detectable levels of
efavirenz in all cell lines in the extracted media
(extracellular) and cell (intracellular) samples. In con-
trast, there was no detectable 8-hydroxyefavirenz in
all cell lines in the extracted media (extracellular) or
cell (intracellular) samples.
Figure 2. Correlation between nanoparticle diameter and CAR in CEM (A), THP1 (B), ATHP1 (C), HepG2 (D), and Caco-2 (E) cells. n = 2 in
duplicate were used for all cell types.
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Transcellular permeability of efavirenz
nanodispersions across Caco-2 cell monolayers
(life science results)
Apparent permeability of the efavirenz SDNs ranged
from 1.14 × 107 to 5.2 × 106 cm/s relative to
1.69 ×106 cm/s for the aqueous control of efavirenz,
with 80.5% (62 out of 77) of the SDNs having a higher
Papp than the efavirenz solution (<0.1% DMSO). As rep-
resented in Figure 3, a signiﬁcant correlation between
z-average diameter and Papp was observed (rho =0.34,
p = 0.003). We have classiﬁed the SDNs in four groups
based on their diameter (from 0 to 100 nm,
100–200nm, 200–300 nm, and above 300 nm). The Papp
is characterised by a signiﬁcant increase for SDNs with
increasing size up to 300 nm, p =0.035. The mean
apparent permeability of the particles characterised
with >300 nm is 73% compared to the SDNs with
diameter< 100nm (p = 0.004) conﬁrming the relevant
Figure 3. Apparent permeability of SDNs. A) Correlation between nanoparticle diameter and apparent permeability across Caco-2 cells.
B) Simulated plasma concentrations trough the PBPK model. The grey lines represent the simulated pharmacokinetics for the SDN with
highest and lowest Papp; black line represents the pharmacokinetics for the traditional formulation. n = 2 in duplicate were used for the
quantiﬁcation of the Papp.
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inﬂuence of size in the deﬁnition of efavirenz perme-
ability through the Caco-2 monolayer. As summarised
in Supplemental Table 7, regression analysis identiﬁed
particle diameter (log10 z-average diameter, β = .32,
p = 0.001) as a predictor of Papp. Also, nanoparticle
composition appeared to be important with F68
(β = .24, p = 0.007) and PVP30k (β = .22, p = 0.0044) be-
ing signiﬁcantly associated with Papp.
Prediction of bioavailability and
pharmacokinetics by PBPK (life science results)
The prediction of plasma pharmacokinetics of the
efavirenz traditional formulation was comparable to
available clinical data (Vrouenraets et al., 2007). Simu-
lated PK variables at steady state (mean ± SD) were
Ctrough (2203 ± 2151 ng/mL), Cmax (2811 ± 2104 ng/mL),
and AUC (59 550 ± 41 423ng/mLh), in agreement with
previous clinical PK data: Ctrough (1752 ± 1001 ng/mL),
Cmax (4037 ± 1158 ng/mL), and AUC (57 592 ±22 849ng/
mLh). Simulated bioavailability (mean ± SD) of the tra-
ditional formulation was 35% ± 2.6%. For context, abso-
lute bioavailability in patients has been estimated to be
around 40% (Chiappetta et al., 2010). As represented in
Figure 3B, the simulated plasma pharmacokinetics of
the SDN with best Papp (5.2 × 10
6 cm/s) resulted in an
increase of 77% in Ctrough, 81% in Cmax, and 80% in AUC
with an absolute bioavailability of 52% ± 3%. Conversely,
the SDN with the worst Pappwas predicted to generate a
decrease of 72% in Ctrough, 76% in Cmax and 74% in AUC
with an absolute bioavailability of 7.2% ±0.8%.
Validation of size model by prediction of Papp for
scaled efavirenz SDNs (life science results)
The Papp-size regression model was validated using six
SDNs with 70wt% efavirenz that were previously de-
scribed and include the existing efavirenz lead formula-
tion (McDonald et al., 2014). The equation describing a
correlation between particle size and Papp was vali-
dated against the Papp experimentally measured for
the six additional SDNs. As shown in Figure 4A, a signif-
icant correlation (r = 0.836, p =0.038) was observed be-
tween the predicted and experimentally determined
Papp. Additionally, a Bland and Altman plot (Fig. 4B)
demonstrated agreement between the predicted and
measured Papp, with all values lying between the 95%
limits of agreement (±2SD).
Discussion
This study focused on the investigation of the pharma-
cological behaviour of efavirenz SDNs and the
identiﬁcation of ideal nanoparticle properties and com-
position. The generated efavirenz SDNs were
characterised by an improved intestinal permeability
and accumulation in different cell lines compared to
an aqueous solution (<0.1% DMSO) of efavirenz. The
physicochemical properties of efavirenz SDNs were de-
scribed and correlated with pharmacological character-
istics in order to rationalise SDN optimisation for
translation. The Papp model was validated against the
previously published lead formulation and backup can-
didates to demonstrate the feasibility of this approach
for future development. The data were important to
select the current efavirenz lead formulation,
progressing towards human trials, and are also of inter-
est to inform future rational development of SDNs with
favourable pharmacological features.
Cell lines used in this study were selected to repre-
sent cell populations with which nanoparticles may in-
teract. The data should be interpreted in the context
that while intestinal enterocytes are encountered by
SDNs after oral administration, SDNs have not been
demonstrated to enter the systemic circulation after
oral or parenteral administration (Liptrott et al.,
2014); however, other APIs are being investigated for
direct intravenous administration as SDNs (Zhang
et al., 2014). Consequently, different routes of admin-
istration may result in distinct distribution patterns be-
cause of potential increased accumulation of SDNs in
tissues. Notwithstanding, Caco-2 cells were selected
to model enterocytes, HepG2 to represent hepato-
cytes, human acute monocytic leukaemia cells (THP1)
and adapted human acute monocytic leukaemia cells
(ATHP1) to model monocytes and macrophages, and hu-
man T lymphocyte cells (CEM) to represent lympho-
cytes. Apparent permeability through a monolayer of
Caco-2 cells is considered as a reliable model to investi-
gate the intestinal absorption of drugs (van Breemen
and Li, 2005).
Efavirenz is characterised by high membrane perme-
ability and low aqueous solubility and classiﬁed as a BCS
Class II drug (da Costa et al., 2012). The dissolution of
this kind of API may be improved by formation of SDNs.
SDNs of other APIs have been clinically demonstrated to
increase intestinal permeability, but the precise mech-
anism for this has not been conclusively shown. The
solubilisation from solid dispersions is regulated by
particle size, surface area, and increased wettability.
Several types of nanoparticles have been developed in
recent years to improve oral absorption and/or cellular
penetration through this mechanism. Improved oral
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bioavailability has been demonstrated by SDN formula-
tions of other APIs (Deschamps et al., 2009; Weir et al.,
2013), and other types of nanoformulation have also
shown promise (Qhattal et al., 2011; Doh et al.,
2013). For example, nanoemulsions of the chemopre-
ventive agent benzyl isothiocyanate showed improved
dissolution proﬁles, enhanced solubility, cellular accu-
mulation, and intestinal permeability compared to tra-
ditional formulations (Qhattal et al., 2011). Similarly, a
nanoemulsion for the antiemetic granisetron resulted
in higher drug dissolution and in vitro permeation in
Caco-2 cells than traditional suspensions (Doh et al.,
2013). Importantly, not all the developed efavirenz
SDNs were predicted to exhibit favourable bioavailabil-
ity compared to the conventional formulation. Appar-
ent permeability through Caco-2 cell monolayers was
higher for 80.5% of the SDNs tested. Because tradition-
ally only very few nanoparticle options are tested for an
individual drug, this dataset provided a unique opportu-
nity to probe which nanoparticle characteristics inﬂu-
ence the observed beneﬁts. To underscore this point,
the effect of SDN formation on efavirenz pharmacoki-
netics was simulated through PBPK modelling. While
the SDN with the highest Papp was predicted to result
in an 80% increase in exposure, the SDN with the lowest
Papp was predicted to result in a 74% decrease of
Figure 4. A) Correlation between predicted and measure Papp for the validation SDNs with 70wt% efavirenz loading. B) Bland and Altman
plot showing agreement between the predicted and measured Papp (within 2SD). n = 2 in duplicate were used for all cell types.
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exposure. These ﬁndings demonstrate that the arbi-
trary application of nanoformulation may generate
unfavourable pharmacokinetic outcomes that may re-
sult in a technology being overlooked without thorough
investigation. The selection of nanoparticle candidates
should be based on a rational analysis of pharmacologi-
cal properties to select lead formulations. Importantly,
size was associated with apparent permeability across
Caco-2 cells, and this association was validated against
independent SDNs containing 70wt% efavirenz relative
to polymer and surfactant excipients. The assumption
that Papp for 70% efavirenz particles is likely to be sim-
ilar to particles with equal size but lower efavirenz con-
tent is important but it should be carefully considered.
This assumption could be tenuous if the surface
coverage/outer layer is not characterised by the excip-
ients and surfactants in both cases. The predicted Papp
was in good agreement with the experimentally deter-
mined Papp, and this approach will have utility for
accelerating development of formulations with
favourable properties for future APIs.
Formation of SDNs also did not guarantee beneﬁts for
cellular accumulation of efavirenz. For the cell lines
ATHP1, HEPG2, and Caco-2, the accumulation in cells
was lower than the traditional formulation for the
97%, 93%, and 79% of tested SDNs, respectively. The
CAR was higher for 73% of SDNs when tested in THP1
cells and 88% in CEM cells indicating preferential
effects for cells in suspension compared to adherent
cells, exempliﬁed by comparing THP1 to ATHP1 cells.
These data indicate that certain SDNs have the poten-
tial of enhancing drug delivery in speciﬁc cell popula-
tions while mitigating penetration to others, and this
warrants further study for passive targeting applica-
tions. To further understand this, additional analysis
of the factors inﬂuencing cellular accumulation was
undertaken. Nanoparticle diameter was correlated
with CAR only in CEM cells. Zeta potential had a positive
inﬂuence on CAR in Caco-2 and HepG2 cells. Polydisper-
sity index was associated with higher CAR in HepG2.
Also, polymers and surfactants appeared to inﬂuence
cellular accumulation in different cell lines. The surfac-
tant, F68, had a positive effect on the apparent perme-
ability in Caco-2 cells and cellular accumulation in
THP1 while having a negative inﬂuence on the accumu-
lation in HepG2 cells. PEG1k negatively inﬂuenced the
accumulation in two cell lines, ATHP1 and Caco-2.
NaCMC had a positive effect on the CAR of ATHP1 and
HepG2. Other nanoparticle components signiﬁcantly
inﬂuencing cellular accumulation were sodium
alginate, Sisterna 16 and Tween 80 for THP1 cells, PVA
and Brij58 for ATHP1, and F127 and Solutol HS for CEM
cells (negative effect on accumulation). CAR in HepG2
was negatively affected by Na deoxycholate and F68.
Additionally, apparent permeability in Caco-2 cells
was positively associated with PVP30k and F68. Several
nanoparticle properties such as composition, surface
chemistry, size, and shape can have an effect on phar-
macokinetics, inﬂuencing uptake and transport in tis-
sues across different technological platforms (Moss
and Siccardi, 2014). The role of structure and surface
functionality on the deﬁnition of ADME properties of
dendrimers have been recently characterised
(Kaminskas et al., 2011). Size was identiﬁed as a pre-
dictor of plasma concentrations and biodistribution for
gold nanoparticle, with small nanoparticles (4 or
13 nm) detectable for up to 7 days in blood, whereas
large (100 nm) nanoparticles were completely cleared
in 24 h (Cho et al., 2010). Additionally, the elimination
processes of polymeric nanoparticles are inﬂuenced by
numerous variables including choice of polymer, size,
charge, and the use of active targeting strategies. A
correlation between charge, size, and clearance has
been observed, with smaller nanoparticle having a
faster clearance (Alexis et al., 2008). Our ﬁndings may
indicate that the mechanisms regulating SND accumula-
tion may differ between cell types. Because the excip-
ients used inﬂuenced the particle properties, it was not
possible to delineate one from the other; however, col-
lectively, these data provide a platform from which to
select excipients forming nanoparticles with physical
properties for favourable pharmacological behaviour.
The presented data indicate that size can be tuned
through appropriate selection of excipients. PVA,
F127, AOT, and cremophor were predictors of smaller
nanoparticle diameter, and NaCMC was correlated with
increased diameter when using this processing tech-
nique. The appropriate selection of polymers and sur-
factant could be an important factor to inﬂuence
nanoparticle size. Nanoparticle surface charge was also
inﬂuenced by the chemical composition, with PVA and
PEG1k associated with a negative zeta potential and
CTAB and hyamine correlating with a positive surface
charge as would be expected as CTAB and hyamine are
industrial cationic surfactants. Previous studies have
also highlighted the importance of nanoparticle compo-
sition, characteristics, and geometry in the deﬁnition
of their pharmacokinetics (Xue et al., 2013; Schrade
et al., 2012). Phagocytosis and cellular accumulation
in macrophages have been shown to be inhibited by a
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combination of elongated shape and PEGylation
(Mathaes et al., 2014). For non-phagocytic cells, the
uptake has been shown to be inﬂuenced by size and
charge with variability between different cell popula-
tions and ambiguous results regarding shape (Kettler
et al., 2014). In our study, size was weakly correlated
with cellular accumulation for CEM cells which are not
characterised by phagocytic uptake and are not adher-
ent. Consequently, it could be hypothesised that spe-
ciﬁc mechanisms only present in cells with similar
characteristics can deﬁne these effects. However, a
universal correlation between nanoparticle properties
and distribution is unlikely considering the broad vari-
ability in available nanotechnologies and the complex
interplay between nanoparticle characteristics and
pharmacokinetics. Also, it remains to be seen whether
similar correlations are observed across APIs or whether
effects are API speciﬁc. Additionally, the selected
methodologies are based on static cell culture and po-
tentially nanoparticle dynamics of uptake and degree
of accumulation can be inﬂuenced by ﬂow of biological
ﬂuids such as intestinal buffer or blood and plasma.
Numerous mechanisms may underpin the higher
accumulation and permeability of SDNs. Nanoparticles
can be taken up into cells following the interaction with
speciﬁc receptors triggering endocytosis, pinocytosis,
or phagocytosis. The cellular entry of polystyrene beads
has been investigated in Hela and MDCK cell lines,
highlighting that nanoparticle internalisation depends
upon clathrin-mediated endocytosis and direct
permeabilisation of the plasma membrane (Smith
et al., 2012). In other studies, the uptake through
phagocytosis by macrophages was clariﬁed for nanopar-
ticles such as polylactic acid nanoparticles (Li et al.,
2013). In the intestine, uptake of nanoparticles has
been described to happen through paracellular path-
ways and transcellularly by enterocytes and Peyer’s
patches via M-cells (Jia, 2005). However, to the best
of our knowledge such experiments have not been con-
ducted for untargeted SDNs. Nonetheless, different
processes are likely to interplay to govern nanoparticle
penetration into cells.
The activity of transporters has a relevant role in me-
diating drug movement through biological membranes
and intracellular penetration. Nanoparticles may be
able to circumvent the action of transporters by
protecting the drug from efﬂux and increasing cellular
accumulation or crossing biological membranes. In this
regard, antiretrovirals, cardiovascular drugs, anti-
cancer agents, antibiotics, and a plethora of other APIs
are substrates of efﬂux transporters such as ABCB1 and
ABCCs (Lee et al., 1998; Togami et al., 2014; Wessler
et al., 2013). Transporters can determine high inter-
patient variability in drug distribution, considering mul-
tiple genetic and environmental factors inﬂuencing
their expression and activity. Additionally, drug–drug
and food–drug interactions are a relevant concern in
several treatments and are often mediated by efﬂux
and inﬂux transporters. Transporters such as ABCB1
have frequently overlapping substrate and inhibitor
speciﬁcities with CYP3A4, and therefore drug–drug in-
teractions can result in complex pharmacokinetics.
The possibility of countering the effect of transporters
on drug distribution is interesting, and excipients in-
cluded in SDN formulation have the potential to alter
the activity of drug metabolism enzymes in vitro
(Martin et al., 2013). The inﬂuence of polymers and
surfactants on transporters and other mechanisms of
drug/nanoparticle accumulation might explain the
broad variability observed between different cell lines
in the current study. However, the effects of many
nanoparticle excipients on the activity and expression
levels of metabolism enzymes and drug transporters
in vivo are not fully understood.
In summary, nanoparticle size and excipient choice
inﬂuenced apparent permeability and cellular accumu-
lation, and this appeared to be cell line dependent.
These data represent a useful platform for the optimi-
sation of SDNs, giving an empirical background for the
selection of composition and physical characteristics.
Understanding how excipients and nanoparticle physi-
cal properties inﬂuence biological phenotypes across
different APIs will enable future rational design of SDNs
with desirable pharmacological properties. The analysis
of property–distribution relationships is essential to in-
form the design of nanoparticle with optimal pharma-
cokinetics and enhanced drug distribution.
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